Biotech | April 12, 2022
Cambrex completes large-scale US API expansion
The expansion positions Cambrex with the largest and most advanced API facility in the United States
The expansion positions Cambrex with the largest and most advanced API facility in the United States
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Subscribe To Our Newsletter & Stay Updated
